European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic MelanomaBusiness Wire • 10/01/21
European Medicines Agency Validates Bristol Myers Squibb's Application for Mavacamten for the Treatment of Obstructive Hypertrophic CardiomyopathyBusiness Wire • 10/01/21
These 3 Dividend Stocks Could Soar Between 23% and 32%, According to Wall StreetThe Motley Fool • 10/01/21
Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic DiseasesBusiness Wire • 09/30/21
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should KnowZacks Investment Research • 09/27/21
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell CarcinomaBusiness Wire • 09/27/21
Bristol Myers Squibb (BMY) Stock Moves -1.32%: What You Should KnowZacks Investment Research • 09/20/21
Bristol Myers' (BMY) Opdivo Combo for Gastric Cancer Gets CHMP NodZacks Investment Research • 09/20/21